Other News To Note
Thursday, February 7, 2013
Oxygen Biotherapeutics Inc., of Morrisville, N.C., said it signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research at Fort Sam Houston, Texas, to explore the potential effects of the firm's perfluorocarbon-based emulsion, Oxycyte, on platelet function and blood hemostasis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.